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Prediction of beneﬁt from combined chemotherapy and the antiepidermal growth factor receptor cetuximab is a not yet solved
question in head and neck squamous cell carcinoma (HNSCC). In a selected series of 14 long progression-free survival (PFS)
and 26 short PFS patients by whole gene and microRNA expression analysis, we developed a model potentially predictive of
cetuximab sensitivity. To better decipher the “omics” proﬁle of our patients, we detected transcript fusions by RNA-seq through
a Pan-Cancer panel targeting 1385 cancer genes. Twenty-seven diﬀerent fusion transcripts, involving mRNA and long
noncoding RNA (lncRNA), were identiﬁed. The majority of fusions (81%) were intrachromosomal, and 24 patients (60%)
harbor at least one of them. The presence/absence of fusions and the presence of more than one fusion were not related to
outcome, while the lncRNA-containing fusions resulted enriched in long PFS patients (P = 0 0027). The CD274-PDCD1LG2
fusion was present in 7/14 short PFS patients harboring fusions and was absent in long PFS patients (P = 0 0188).
Among the short PFS patients, those harboring this fusion had the worst outcome (P = 0 0172) and increased K-RAS activation
(P = 0 00147). The associations between HNSCC patient’s outcome following cetuximab treatment and lncRNA-containing
fusions or the CD274-PDCD1LG2 fusion deserve validation in prospective clinical trials.
1. Introduction
The therapeutic opportunities for recurrent and/or metasta-
tic (RM) head and neck squamous cell carcinoma (HNSCC)
may be divided into 3 modalities: (i) potentially salvageable
treatments, like (re)irradiation or salvage surgery; (ii) pal-
liative systemic therapies, such as chemotherapy and/or
targeted agents; and (iii) the best supportive care. Salvage
therapies are the ﬁrst options, but their feasibility is limited
by the patient’s performance status or by other prognostic
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factors as disease-free interval as well as by technical aspects
such as the site and extension of disease or to the previous
administered treatments [1–3].
First line palliative systemic therapy is represented by the
combination of platinum-based chemotherapy and cetuxi-
mab, an antiepidermal growth factor receptor (EGFR) agent.
This combination, as shown in the pivotal EXTREME trial, is
able to achieve a clinical response in more than one-third of
the patient, and it is able to statistically improve overall
survival (OS) and progression-free survival (PFS) and it
improves the patient’s quality of life, when compared to
chemotherapy alone [4]. However, the median OS is of 10.1
months with more than 80% of the patients experiencing
one grade 3 or 4 adverse event. Thus, the presence of multiple
mechanisms of intrinsic resistance to this therapeutic combi-
nation exposes some patients to the double-negative eﬀect of
drug toxicity and disease unresponsiveness.
Therefore, the issue of predicting which patient will
beneﬁt from this approach is an outstanding question in head
and neck oncology. In fact, all the eﬀorts in identifying
speciﬁc alteration in EGFR status (studied by immunohisto-
chemistry, ampliﬁcation, or mutation) did not reach their
purpose [5–7].
A solution might, however, lie with a molecular approach
[8, 9], judging also from the encouraging results of our
predictive models, developed to test cetuximab sensitivity in
RM-HNSCC patients [10, 11].
Speciﬁcally, we implemented a model of cetuximab and
chemotherapy (CT) sensitivity analyzing the 2 extremities
of responsiveness to the drugs, represented by patients
achieving a long PFS, deﬁned to be more than 1 year, and
patients showing a short PFS, deﬁned to be less than 5.6
months, that is, the median PFS of the EXTREME trial. Using
these selected patient cohorts and applying, as ﬁrst, gene
expression analysis [10] and in a second study an integrative
analysis of miRNA and mRNA expression [11], we identiﬁed
speciﬁc proﬁles corresponding to the long and short PFS [10]
and a height miRNA gene-integrated signature with an excel-
lent accuracy in predicting treatment response [11]. Trying
to better decipher the diﬀerent biological molecular charac-
teristics of the extremities of the response curve to cetuximab
CT, we decided to explore the new area of fusion transcripts
in the search of other complementing genomics.
Gene fusions could occur by structural rearrangements
or by transcription read-through of neighboring genes,
being the second mechanism responsible for a large pro-
portion of gene fusions (see [12] for a recent computation-
ally oriented literature review); their clinical utility in
cancer as biomarkers for prognosis or diagnosis is proven,
and some fusion proteins are promising therapeutic targets
(see [13] for the landscape of cancer-associated transcript
fusions). At present, 300 samples of the TCGA-HNSCC
dataset were characterized for the presence of transcript
fusions [12], and among the identiﬁed fusion events,
FGFR3-TACC3 fusion was detected in two HPV-positive
tumors. Subsequently, in a HNSCC cell model system
[14], the signaling by FGFR3-TACC3 fusion protein was
further characterized as a novel mechanism of resistance
to EGFR/ERBB3 inhibition. A limited number of other
reports focused on gene fusions in HNSCC samples [15]
or cell lines [16–17].
No data are presently available in a clinical setting about a
possible association between gene fusion presence and
response to a targeted therapy, such as the one with EGFR
inhibitors. Taking again the advantage of the RM-HNSCC
clinical material already genomically characterized by us
[10, 11], we looked for the expression of fusion transcripts
derived from 1385 diﬀerent genes, selected on the basis of
their putative role in cancer, as potential markers of intrinsic
sensitivity/resistance to cetuximab CT.
2. Materials and Methods
2.1. Patients and Study Design. Forty formalin-ﬁxed paraﬃn-
embedded (FFPE) tumor specimens from RM-HNSCC
patients treated between 2008 and 2012 with ﬁrst-line plati-
num and cetuximab-based combination were collected and
divided according to PFS following cetuximab CT treatment
in long (14 patients) and short PFS (26 patients) as detailed in
[10]. Brieﬂy, the two groups were balanced for known prog-
nostic factors [18] (primary tumor site, performance status,
weight loss, prior radiotherapy, tumor grade, residual disease
at primary tumor site, age, and gender). Long PFS had a
median PFS of 19 months (range 12–36) while short PFS
had a median PFS of 3 months (range 1–5.5).
2.2. Transcript Fusion Detection. To detect transcript fusions
in RM-HNSCC, the TruSight RNA Pan-Cancer panel
(Illumina) targeting 1385 cancer genes, including 507 known
genes involved in fusions and 878 genes either mutated or
deregulated in cancers, was used according to the provider’s
protocol. The panel design covers all exons and 160 bp at
the 5′ and 3′UTR of every gene. Brieﬂy, cDNA is generated
from 50ng of total RNA from the FFPE specimens using
random priming. After second strand synthesis, sequencing
adapters are ligated to the double-stranded cDNA fragments.
The coding regions of expressed cancer-associated genes
were captured from 200ng of this library using sequence-
speciﬁc probes to create the ﬁnal sequencing library. Quality
check was performed using 4200 TapeStation and D1000
ScreenTape Assays (Agilent) yielding libraries with a band
peak at ~250–300 bp. Samples were equimolarly pooled and
sequenced on a NextSeq500 sequencer using the NextSeq500
High Output Kit v2 (150 cycles) chemistry (Illumina) to
obtain 40M/sample paired end reads of length 2× 75 bps.
The data processing was performed on BaseSpace
Sequence Hub, a dedicated genomics computing environ-
ment for data management and analysis applying TopHat
Alignment v1.0. TopHat Alignment workﬂow allows the fol-
lowing functions: (i) read mapping on homo sapiens UCSC
hg19 through the TopHat 2 aligner and (ii) fusion calling
with TopHat-Fusion [19]. After the alignment of sequencing
reads within the exon regions, the reads not entirely aligned
were divided into multiple segments of 25 bp. It is expected
that the initially unmapped reads contain sequencing por-
tions residing on diﬀerent chromosomes or on the same
chromosome but, after rearrangement, representing poten-
tial fusion candidates. The ﬁrst and last 25 bp portions were
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aligned on the genome through Bowtie. When an alignment
pattern is detected, the entire read sequence is used to iden-
tify the fusion point by stitching segments to obtain the full
read alignment. The oligo capture approach of the TruSight
RNA Pan-Cancer panel allows pulling down one target gene
among the 1385 genes in the panel and the partner fusion not
necessarily included in the panel. Since the TopHat-fusion
algorithm works independently of the information about
known genes, it can also lead to the identiﬁcation of novel
fusion products. To avoid false positive calls, candidate gene
fusions were ﬁltered out imposing the following parameters:
(i) intrachromosome fusions have to be separated by
100.000 bp distance; (ii) spanning reads on both sides should
have at least 13 bp; and (iii) reads map to multiple locations
(>2). The annotated gene fusions were then displayed using
the OmicCircos software package [20] with respect to
genomic position using the hg19 reference.
2.3. Characteristics of Genes Present in Transcript Fusion. The
information on genes/lncRNA was retrieved from https://
www.ncbi.nlm.nih.gov/gene and https://lncipedia.org/ [21]
(version 4.1, May 4, 2017, containing 146,742 human-
annotated lncRNAs) and http://cancer.sanger.ac.uk/cosmic
and https://cancergenome.nih.gov/.
The presence of fusion transcripts in cancers was
searched in the following websites: Pubmed (https://www.
ncbi.nlm.nih.gov/pubmed) and TCGA fusion gene data
portal (http://54.84.12.177/PanCanFusV2/).
2.4. Functional Analysis. To disclose the molecular pathways
associated with CD274/PDCD1LG2 fusion, we retrieved
gene expression data from Bossi et al. [10] deposited on
GEO repository (GSE65021). Gene set enrichment was
investigated by gene set enrichment analysis (GSEA) [22]
analyzing seven oncogenic signatures found in our previous
studies [10, 11] and including β-catenin, E2F3, EGFR, KRAS,
MYC, NOTCH, and p53. To graphically represent the signif-
icant gene sets and to display their enrichment signiﬁcance,
we used Enriched Map implemented as a Java plugin for
the freely available Cytoscape network visualization and
analysis software [23].
2.5. Statistical Analysis. The presence of fusions in long and
short PFS as well as of speciﬁc fusions was evaluated using
the Fisher exact test through GraphPad Prism software pack-
age. A P value equal or <0.05 was considered to indicate
statistical signiﬁcance. Diﬀerences in PFS between patients
harboring or not CD274/PDCD1LG2 fusion among the 26
short PFS patients were assessed using log-rank test and R
package survival [24].
3. Results and Discussion
With the aim to disclose the biological features associated
with cetuximab sensitivity in RM-HNSCC, we applied an
RNA-seq approach through a Pan-Cancer panel to a selected
cohort [40 patients treated with platinum- and cetuximab-
based combination and having long PFS (n = 14) and short
PFS (n = 26)].
Based on the applied workﬂow of analysis, 27 diﬀerent
fusion transcripts were identiﬁed; Figure 1 shows the geno-
mic landscape of the identiﬁed transcript fusions that is
further detailed in Supplementary Table 1 available online
at https://doi.org/10.1155/2017/6870614. Twenty-two out of
twenty-seven (81%) fusion transcripts were intrachromoso-
mal and located in neighboring genes while 5 resulted from
structural rearrangements and translocations to a diﬀerent
chromosome. The identiﬁed transcript fusions involved rear-
rangements in all, but Chr7, Chr10, Chr18, Chr20, and ChrY,
chromosomes; Chr3, Chr11, and Chr22 harbor three diﬀer-
ent fusions and high level of gains (ratio> 1.5) at 11q13,
and their association with poor survival has been described
in HNSCC (see [25]); Chr1, Chr2, Chr8, Chr9, Chr14, and
Chr19 harbor two fusions. The total number and chromo-
somal distribution of the identiﬁed fusion transcripts are
essentially in agreement with data already reported in
HNSCC samples [13–15] even if the comparison is diﬃcult
due to the diﬀerent approach adopted (targeted versus whole
genome) (see below). In all the HNSCC studies on clinical
samples, including the present one, fusion transcripts result-
ing from translocations are relatively rare while the majority
is generated by nonstructural rearrangement mechanisms,
such as transcription read-through of neighboring genes or
splicing of mRNA molecules. This type of gene fusions is
reported to be preferentially derived by genomic instability
(see [12] for review of the mechanisms).
Twenty-four patients (60%) harbor at least one of the 27
identiﬁed transcript fusions; the presence and main charac-
teristics of gene fusions detected in each RM-HNSCC patient
of our selected case material are reported in Table 1 (see [10]
for clinical pathologic characteristics of the patients). We
investigated whether the presence of transcript fusions is
associated with long or short PFS under cetuximab treat-
ment: 10/14 (71%) long PFS cases and 14/26 (54%) short
PFS harbor at least one fusion; however, the presence or
absence of fusions is not signiﬁcantly related with outcome
(Table 2). The chromosomal rearrangements in cancer cells
could also lead to multiple fusion events. Fifteen and 9 cases
harbor only one transcript fusion and more than one, respec-
tively (Table 2); in detail, 3 patients harbor 2 fusions, 4
patients 3 fusions, 1 patient 4 fusions, and 1 patient 6 fusions;
nine fusions are present in two or more patients (Table 1).
Since the coexistence of multiple fusions might mirror the
extent of aberrations present in the tumor, we investigated
whether the presence of more than one fusion is associated
with outcome under cetuximab. Five out of the 10 long
PFS and 4/14 short PFS cases presented more than one
fusion, but this diﬀerence did not reach a signiﬁcant level
(Table 2). The accumulation of transcript fusions may be
associated with tumor progression; since in our case mate-
rial the RNA was obtained in 9 cases from samples taken at
recurrence/metastasis, we analyzed whether in this sub-
group of patients (9/40) the presence/number of transcript
fusions was higher. Eight out of 9 recurrent/metastatic
cases (89%) harbor at least one fusion compared to 16/31
(52%) cases from primary lesions; although the diﬀerence
did not reach a signiﬁcant level (P = 0 06), a trend was
clearly appreciable.
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The 27 transcript fusions involve both mRNA and
lncRNA, being 21 mRNA-mRNA, 3 lncRNA-mRNA, 2
mRNA-lncRNA, and 1 lncRNA-lncRNA. The lncRNA-
containing fusions are enriched in long PFS patients with
8/10 and 2/14 in long and short PFS cases, respectively, har-
boring a lncRNA fusion (P = 0 0027). Two fusions involving
lncRNA, ENSG00000231669-MSN, and ENSG00000231121-
NAV3, were each detected in three long PFS patients. At pres-
ent, while lncRNAs are relatively well-characterized, being
involved in the regulation of numerous cellular processes
and being associated with cancer development and progres-
sion [26], little is known about their role in lncRNA-
containing fusions. The current fusion-detection algorithms
and bioinformatics pipelines are focused on recognizing fusion
candidates mapping to protein-coding mRNA systematically
omitting lncRNA [12]. As a result, only a handful of gene
fusions containing lncRNAs has been reported [27]. Some
studies highlighted a biological, functional, and even clinical
relevance of speciﬁc mRNA/lncRNA fusions proving that
these lncRNAs might contribute to the aberrant regulation of
their partner [12]. The identiﬁcation of lncRNA-containing
fusions was achieved in our case material due to the adopted
targeted approach. We selected this approach, instead of
RNA-seq used with the 300 HNSCC [13] and the 47 oral squa-
mous cell carcinoma (OSCC) [15], due to the availability of
only archival FFPE samples whose RNA-seq analysis may
result limited, as recently highlighted in another cancer type
by direct comparison of paired frozen and FFPE samples [28].
Several studies of gene fusion networks have found
that the majority of fusion genes partner with a single
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Figure 1: Circos plot of the genomic landscape of gene fusions identiﬁed by RNA-seq in our 40 RM-HNSCC samples. The outer ring displays
the chromosome ideograms. The fusion transcripts are shown as line arcs linking the two genomic loci.
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Table 1: Presence and main characteristics of gene fusions detected in each RM-HNSCC patient of our selected case material; see [10] for
clinical pathologic characteristics of the patients.
Sample ID Gene fusion
“Left” partner “Right” partner
Gene Chromosome Gene Chromosome
Short PFS under chemotherapy-cetuximab treatment
GU05 No
GU09 No
GU10 Yes
DLG2 Chr11 PICALM Chr11
NUMA1 Chr11 GRIA3 ChrX
ZMYM2 Chr13 TRIM28 Chr19
GU11 No
GU13 Yes CLTC Chr17 RPS6KB1 Chr17
GU14 Yes CD274 Chr9 PDCD1LG2 Chr9
GU15 No
GU17 No
GU18 No
GU20 Yes CD274 Chr9 PDCD1LG2 Chr9
GU21 No
GU22 No
GU23 No
GU24 Yes BMS1P20 Chr22 IGLL5 Chr22
GU25 Yes CD274 Chr9 PDCD1LG2 Chr9
GU26 Yes FGF12 Chr3 MB21D2 Chr3
GU27 No
GU28 Yes
METTL13 Chr1 DNM3 Chr1
CTNNA2 Chr2 HES1 Chr3
RPS6KA2 Chr6 RNASET2 Chr6
MUSK Chr9 LPAR1 Chr9
CD274 Chr9 PDCD1LG2 Chr9
TRAF3 Chr14 ENSG00000259717 Chr14
GU29 Yes CD274 Chr9 PDCD1LG2 Chr9
GU30 Yes RCSD1 Chr1 MPZL1 Chr1
GU31 Yes
CD274 Chr9 PDCD1LG2 Chr9
PPP6R3 Chr11 MLL Chr11
GU34 Yes
NUMA1 Chr11 GRIA3 ChrX
ZMYM2 Chr13 TRIM28 Chr19
GU38 No
GU40 No
GU41 Yes PVT1 Chr8 ENSG00000253288 Chr8
GU43 Yes CD274 Chr9 PDCD1LG2 Chr9
Long PFS under chemotherapy cetuximab treatment
GU04 Yes FLNB Chr3 ENSG00000245384 Chr4
GU06 No
GU07 Yes
METTL13 Chr1 DNM3 Chr1
MUSK Chr9 LPAR1 Chr9
ENSG00000231669 ChrX MSN ChrX
GU08 Yes ENSG00000231669 ChrX MSN ChrX
GU12 Yes
C9 Chr5 RCOR1 Chr14
ENSG00000259446 Chr15 RYR3 Chr15
IGLV1-40 Chr22 IGLL5 Chr22
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other gene, but it is known that some genes might recom-
bine with multiple partners being the MLL the extreme
example, described to fuse with over 60 diﬀerent partner
genes [29]. In our study, MLL was present in a single
fusion while IGLL5 recombined with BMS1P20 and IGL1-40
(see Supplementary Table 1).
The distribution and the gene partners of our 27 fusion
transcripts were compared with the 382 and the 282 fusions
detected by a whole genome approach in HNSCC [13] and
OSCC [15], respectively; we recorded a 33% of fusions shared
among more patients and no overlap with fusions previously
identiﬁed in HNSCC/OSCC. The diﬀerent results could be
mainly attributed to the use of a panel that enabled a higher
sequencing depth but that was biased toward cancer genes.
Despite these diﬀerences, one or both gene partners of our
27 fusions was/were present in association with other genes
in the 7887 high conﬁdence fusion transcripts identiﬁed in
4366 primary tumor samples from 13 tumor types including
HNSCC (Supplementary Table 1).
We analyzed the characteristics of the gene partners
(see details in Supplementary Table 1) to potentially deﬁne
the molecular functions of the identiﬁed fusions, and we
observed that chromatin modiﬁers (KMTA2-MLL, RCOR1,
and KAT6A), kinases (RPS6KA, MUSK, TRIM28, MPZL1,
andMAP2K2), and phosphates (LPAR1, PICALM,RPS6KB1,
DLG2, PPP6RB, TPTA, and PI4KA) were frequently present.
Worth mentioning, the fusion CD274-PDCD1LG2 was
present as single fusion (5/14) or associated with other
Table 1: Continued.
Sample ID Gene fusion
“Left” partner “Right” partner
Gene Chromosome Gene Chromosome
GU16 Yes WDR90 Chr16 RHOT2 Chr16
GU19 Yes
ANK1 Chr8 KAT6A Chr8
ZBTB7A Chr19 MAP2K2 Chr19
GU32 Yes
ZBTB7A Chr19 MAP2K2 Chr19
TPTE Chr21 BAGE2 Chr21
ENSG00000231669 ChrX MSN ChrX
GU33 Yes ENSG00000231121 Chr12 NAV3 Chr12
GU35 No
GU36 Yes
ZC3H15 Chr2 ITGAV Chr2
PPP6R3 Chr11 MLL Chr11
ENSG00000231121 Chr12 NAV3 Chr12
PI4KA Chr22 CRKL Chr22
GU37 Yes ENSG00000231121 Chr12 NAV3 Chr12
GU39 No
GU42 No
Table 2: Summary of the gene fusions detected in patients treated
with cetuximab and chemotherapy and selected for the extremities
of response (see [10]).
Patients harboring
gene fusions
N (%)
P value§
Long PFS (14) Short PFS (26)
Absence 4/14 12/26
0.3295§
Presence 10/14 14/26
1 for each patient 5/10 10/14
0.4028§>1 for each patient 5/10 4/14
Only mRNA in the
fusion
6/10 13/14 0.1222§
LncRNA in the fusion 8/10 2/14 0.0027§
CD274/PDCD1LG2
fusion
0/10 7/14 0.0188§
§The P values are reported as the two-sided Fisher exact test.
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Figure 2: Kaplan-Meier curves showingPFSamongpatientswith the
presence or absence of the CD274-PDCD1LG2 fusion transcript.
Median PFS: 2.2 months in the group with fusion (n = 7) and 3.4
months in the group not harboring the fusion (n = 19) (P = 0 0172).
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fusions (2/14) in short PFS patients while it was absent in all
long PFS patients (P = 0 0188). CD274-PDCD1LG2 fusion
deﬁned a subgroup into short PFS; in fact, by Kaplan-Meier
analysis, the median estimates of PFS in patients harboring
or not the fusion were 2.2 and 3.4 months, respectively
(P = 0 0172 by the log-rank test) (Figure 2). Thus, we investi-
gated the biology behind the CD274-PDCD1LG2 fusion in
the short PFS cases analyzing molecular pathways through
GSEA. The oncogenic signatures reported in our previous
studies [10, 11] were tested for their enrichment in cases
harboring CD274-PDCD1LG2 fusion, and as reported in
the enrichment map (Figure 3), KRAS (P = 0 00147;
NES= 1.62) is enriched in cases with the fusion, while EGFR
(P = 10E‐04; NES=−2.04), p53 (P = 10E‐04; NES=−1.83),
NOTCH (P = 10E‐04; NES=−1.82), and β-catenin (P = 10
E‐04; NES=−2.04) onco-signatures are enriched in cases
without the fusion. E2F3 and MYC are not signiﬁcantly dif-
ferent between cases with the presence or absence of fusion.
Both partner genes are in the 9p24.1 locus, a region of
recurrent structural and copy number alterations in hemato-
logic tumors, and this fusion was present in 20% of primary
mediastinal large B-cell lymphoma and in lower percent in
other lymphomas [30]. Furthermore, in lymphomas, the rear-
rangement was signiﬁcantly correlatedwith overexpression of
PDL transcripts [30]. The products of the gene partners of our
most frequent fusion transcript, CD274 and PDCD1LG2, also
known as programmed death ligand-1 and 2 (PD-L1 and
PD-L2), respectively, have been implicated in promoting
tumor cell immune evasion acting as negative regulators
of antitumor immunity by binding their cognate receptor,
PD-1, on cytotoxic T-cells. No data are presently available
about this fusion in other types of solid tumors, and our obser-
vation that RM-HNSCC cases harboring CD274-PDCD1LG2
fusion have poor prognosis and resistance to cetuximab
deserve further analysis and validation in wider series of
patients entered/entering in anti-EGFR-targeted trials.
Recently, high PD-L1 expressionwas identiﬁed as a strong
prognostic factor of HNSCC patient’s worse outcome [31].
Within clinical trials with immune checkpoint inhibitors
(CPIs) in RM-HNSCC, higher response rates were noted in
patients with higher PD-L1 expression [32, 33]. However,
other PD-1 ligands could be crucial in determining the eﬃ-
cacy of CPIs. As it has been recently showed, the coexpression
of both PD-L1 and PD-L2 in tumoral specimens of patients
treated with pembrolizumab correlated with higher respon-
siveness to this drug [34]. Further investigation is required
into the role of the CD274-PDCD1LG2 fusion as pharma-
cogenomics biomarker not only as a prognosticator in
RM-HNSCC patients but also as a possible predictive bio-
marker of immunotherapy response to better select patients
for a tailored treatment approach.
4. Conclusions
Transcript fusions resulting from chromosomal rearrange-
ments are genetic alterations well-known from decades
and they can in oncology (i) serve as diagnostic markers,
(ii) provide insight into tumor biology, and (iii) serve as spe-
ciﬁc therapeutic targets. By an RNA-seq approach through a
dedicated Pan-Cancer panel, we investigated the presence
and role of transcript fusions as potential pharmacogenomic
markers of RM-HNSCC patients’ response to cetuximab
and platinum-based chemotherapy. We identiﬁed 27 diﬀer-
ent fusion transcripts and observed signiﬁcant associations
between lncRNA-containing fusions and patient’s better
outcome and the presence of the CD274-PDCD1LG2 fusion
and worst outcome. These observations deserve the testing
in clinical trials but if conﬁrmed, as seen with other gene
fusions in other tumor entities, they could open the way to
a more tailored therapeutic approach. Further on, combina-
tion treatments with only immune therapeutic approaches
or with targeted agents or classic chemotherapy could be
of major importance to increase eﬃcacy and outcome in
RM-HNSCC patients. In this regard, our ﬁndings are impor-
tant to be acknowledged and could lead to further researches
and new trial designs.
𝛽-catenin
NOTCH 
p53
KRAS
EGFR
Figure 3: Enrichment map visualizing results of GSEA analysis for cases with the presence/absence of the CD274-PDCD1LG2 fusion. Seven
oncogenic signatures inferred from our previous studies [10, 11] were tested, and ﬁve resulted a signiﬁcant diﬀerence (oncogenic
signature = node). Node size: number of genes in the gene set. Node color: red = enriched in cases harboring the CD274-PDCD1LG2
fusion. Blue = enriched in cases not harboring the fusion. Edges: connect signiﬁcantly overlapping gene sets (width reﬂects the degree of
the overlap).
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